Search

Author/Creator Berg, S

1. A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN'S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY. (21st February 2022)

Authors:
Panaccione, R; Ferrante, M; Feagan, B G; Sandborn, W; Panes, J; Peyrin-Biroulet, L; Colombel, J; Schreiber, S; Dubinsky, M; Baert, F; Hisamatsu, T; Neimark, E; Huang, B; Liao, X; Song, A; Berg, S; Duan, W; Pang, Y; Pivorunas, V; Kligys, K
Journal:
Journal of the Canadian Association of Gastroenterology
Issue:
Volume 5(2022)Supplement 1
Page Start:
43
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. DOP84 Risankizumab maintenance therapy results in sustained improvements in endoscopic outcomes in patients with moderate to severe Crohn's Disease: Post-hoc analysis from the phase 3 study FORTIFY. (21st January 2022)

Authors:
Irving, P M; Abreu, M; Axler, J; Gao, X; Torres, J; Neimark, E; Song, A; Wallace, K; Kligys, K; Berg, S; Liao, X; Panaccione, R
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i127
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. DOP88 Effect of risankizumab on patient-reported outcomes in patients with Crohn's Disease who had an inadequate response or intolerance to conventional and/or biologic treatments: Results from phase 3 MOTIVATE and ADVANCE trials. (27th May 2021)

Authors:
Peyrin-Biroulet, L; Louis, E; Ghosh, S; Lee, S D; Griffith, J; Wallace, K; Berg, S; Loftus, E V
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S119
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗